Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0261

NEWS & VIEWS

Beyond Regorafenib for Hepatocellular Carcinoma: Next – generation Perspectives.

George Glantzounis, MD, PhD.

Affiliation: George Glantzounis, Associate Professor of Surgery, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.

E-mail: gglantzounis@hotmail.com

Abstract.
Despite the lack of effective adjuvant chemotherapy and/or targeted therapy for resectable hepatocellular carcinoma (HCC), standardization of complete tumor resection (R0) with hepatectomy or atypical liver tumor resection is currently associated with 5-year recurrence and overall survival rate of 60%. The recent approval of regorafenib by the US Food and Drug Administration (FDA)1 for unresectable or metastatic HCC, guarantees the conduction of phase III randomized controlled trials (RCTs) evaluating the efficacy of regorafenib in the adjuvant setting. Although the multi-kinase inhibitor regorafenib is more effective than sorafenib, the recent failure of sorafenib  to provide to provide positive results in a phase III RCT in the adjuvant setting, limits the expectation of regorafenib in the early stage tumors after surgical resection.
This opinion article discusses strengthens and limitations of regorafenib and explains challenges and future perspectives of NGS technologies to discover novel both biomarkers and therapeutic targets for a more precise predictive mutation and molecular comprehensive targeting of individual patients with early or advances HCC.

(Citation: Gastric & Breast Cancer 2017; 12(2): 73-78)

Back

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 August 2017